-
Uncategorized1 month ago
Axsome wins first non-antipsychotic FDA approval for Alzheimer’s agitation
Alzheimer’s disease agitation could mean peak sales of over $2.1 billion for Axsome’s Auvelity, according to analysts at William Blair.
-
Uncategorized1 month ago
AstraZeneca’s breast cancer drug fails to earn backing of FDA advisory committee
Members of the FDA’s Oncologic Drugs Advisory Committee questioned the design of AstraZeneca’s Phase 3 trial of camizestrant, which involved switching treatments at the point of...
-
Uncategorized1 month ago
Corcept ties ALS drug to improved 2-year survival as Phase 3 start date nears
Corcept Therapeutics’ ALS drug was linked to an 87% reduction in the risk of death, a result the biotech hopes to replicate in an upcoming Phase...
-
Uncategorized1 month ago
Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debut
A trio of biotechs priced their IPOs on Thursday into Friday morning, setting the stage for their public trading debuts with more than $850 million combined....
-
Uncategorized1 month agoApproaches to Reducing Toxicity and Side Effects in Cell and Gene Therapy
Cell and gene therapy encompasses a broad range of therapeutic interventions for diseases that have proved refractory to treatment with conventional pharmaceutical approaches. Perhaps the most...
-
Uncategorized1 month ago
FDA taps Szarama as acting CBER director as Prasad’s tumultuous tenure ends
Katherine Szarama, who has served as Prasad’s deputy at the Center for Biologics Evaluation and Research since December, joins a long list of temporary leaders at...
-
Uncategorized1 month agoSTAT+: Her daughter Mila got a bespoke medicine. Now she’s starting a new biotech to make more
ROME — Julia Vitarello, whose daughter Mila eight years ago received a bespoke medicine designed for her particular disease-causing mutation, said this week that she is...
-
Uncategorized1 month ago
Don’t toss cannabis leaves: Scientists found rare compounds with medical potential
Scientists have uncovered a surprising new layer of complexity in Cannabis, identifying dozens of previously unknown compounds—including the first-ever evidence of rare molecules called flavoalkaloids in...
-
Uncategorized1 month ago
‘M&A used to be the only way to go’: Why Seaport’s CEO opted for route to upsized $255M IPO
“We want to develop those programs as far as we can ourselves,” Seaport CEO Daphne Zohar told Fierce.
-
Uncategorized1 month agoTwo biotechs raise a combined $556M in latest spurt of IPOs
Seaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a stretch of large IPOs this year that collectively...
